YouScript® clinical decision support (CDS) tool, is an evidence-based, algorithm-driven software service that identifies all classes of medication interactions (drug-drug, drug-gene, and cumulative drug and/or gene interactions). It calculates the cumulative effects of multiple interactions between prescription drugs, over the counter medications, herbal preparations, and pharmacogenomic data when available. The CDS predicts AUC changing pharmacokinetic interactions from known metabolic data such as the (Ki) of DME inhibiting and inducing drugs and percentage metabolism of drug substrates by affected enzymes. The pharmacokinetic interactions considered by the algorithm include alterations to absorption, distribution, metabolism, and excretion. Metabolism and excretion include phase 1 reactions by cytochrome P450s, esterases, and others, phase 2 reactions considered include glucuronidation and sulfation.
A more robust description of the algorithm is available from the relevant US patents (http://www.google.com/patents/US8311851; http://www.google.com/patents/US8099298). Drug dosage or hepatic or kidney function are not currently taken into account by the algorithm.
Example of the personalized prescribing report generated by the YouScript® Clinical Decision
Support Tool system For each tested patient, a personalized prescribing report was curated by a pharmacist for the patient's physician to review. A YouScript® personalized prescribing report contains the patient's genetic results, the patient's medication list, and a list of prescribing suggestions for the physician to review. An example of the personalized prescribing report generated by the YouScript® system and pharmacogenetic laboratory test report is included as an appendix below. Decreased effectiveness of codeine.
Increase codeine dose for pain control as necessary.
Potential alternatives to codeine for pain include: hydromorphone (Dilaudid), morphine (MS Contin) and oxymorphone (Opana).
DRUG-DRUG INTERACTIONS Impact Medication Cause(s) Effects & Management
Zocor gemfibrozil Coadministration of gemfibrozil and Zocor is contraindicated.
Zocor active metabolite levels may increase by 76-200%.
Increased risk of rhabdomyolysis and myopathy.
Avoid coadministration of gemfibrozil and Zocor if possible.
Potential alternatives to gemfibrozil include: fenofibric acid (Trilipix) and fenofibrate (Tricor).
DRUG-GENE INTERACTIONS Impact Medication Cause(s) Effects & Management

Paxil
CYP2D6 Intermediate Metabolizer
Paxil levels may increase by 26-75%.
Increased risk of weakness, sexual dysfunction, somnolence, sweating and nausea.
Decrease Paxil dose if necessary.
Potential alternatives to Paxil include: vilazodone (Viibryd), mirtazapine (Remeron) and desvenlafaxine (Pristiq).
ALTERNATE MEDICATIONS BEING CONSIDERED Impact Medication Cause(s) Effects & Management
Celexa
CYP2C19 Poor Metabolizer
Celexa levels may increase by 76-200%.
Increased risk of dry mouth, sexual dysfunction, somnolence, QTc prolongation and nausea.
Initiate Celexa dose at 50% of normal in CYP2C19 Poor Metabolizer patients.
Limit Celexa dose to 20 mg daily in CYP2C19 Poor Metabolizer patients.
The YouScript software and Personalized Prescribing Report are clinical decision support tools intended to add to the information healthcare practitioners have available when evaluating and prescribing medications. The recommendations provided may be based on limited patient information and do not supersede sound clinical judgement. Minor interactions and small changes in drug levels that may impact the patient are generally not reported. The healthcare practitioner has responsibility for all treatment decisions independent of the available genetic test results and any information provided by YouScript software, reports or consultations. 
